Acupoint Application for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer
Acupoint Application Combined With 5-HT3 Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: A Single-Center, Randomized, Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Xiu HUANG
- Phone Number: +8615023119040
- Email: 104100275@qq.com
Study Locations
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 402160
- Recruiting
- The Affiliated Yongchuan Hospital of Chongqing Medical University
-
Contact:
- Xiu HUANG
- Phone Number: +8615023119040
- Email: 104100275@qq.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pathologically or cytologically confirmed lung cancer.
- Scheduled to receive first-line platinum-based chemotherapy.
- Aged 18 to 75 years.
- Karnofsky Performance Status (KPS) score ≥ 60.
- Expected survival ≥ 3 months.
- Voluntarily signed written informed consent.
Exclusion Criteria:
- Known allergy to any component of the acupoint plaster.
- Severe skin disease, infection, or breakdown at the planned acupoint sites. --Pregnant or lactating women.
- Cognitive impairment or psychiatric disorder that prevents completion of study assessments.
- Participation in another interventional clinical trial within 30 days prior to enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Acupoint application plus 5-HT3 receptor antagonist
Participants receive herbal acupoint plaster applied to selected acupoints plus standard 5-HT3 receptor antagonist prophylaxis before and during one cycle of platinum-based chemotherapy.
|
Standard antiemetic prophylaxis for chemotherapy-induced nausea and vomiting.
Herbal plaster applied to selected acupoints to alleviate chemotherapy-induced nausea and vomiting.
|
|
Active Comparator: 5-HT3 receptor antagonist alone
Participants receive standard 5-HT3 receptor antagonist prophylaxis alone before and during one cycle of platinum-based chemotherapy.
|
Standard antiemetic prophylaxis for chemotherapy-induced nausea and vomiting.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complete response rate of delayed-phase CINV (24-120 h)
Time Frame: 24 to 120 hours after the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)
|
Complete response is defined as no emetic episodes and no rescue antiemetic use during 24 to 120 hours after the first cycle of platinum-based chemotherapy.
The outcome will be compared between the acupoint application plus 5-HT3 receptor antagonist group and the 5-HT3 receptor antagonist alone group.
|
24 to 120 hours after the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complete response rate of acute-phase CINV (0-24 h)
Time Frame: 0 to 24 hours after the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)
|
Complete response is defined as no emetic episodes and no rescue antiemetic use during 0 to 24 hours after the first cycle of platinum-based chemotherapy.
|
0 to 24 hours after the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)
|
|
MAT nausea score
Time Frame: During the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)
|
Nausea severity measured by the Morrow Assessment of Nausea and Emesis (MAT) questionnaire after the first cycle of platinum-based chemotherapy.
|
During the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)
|
|
FLIE quality-of-life score
Time Frame: During the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)
|
Quality of life assessed by the Functional Living Index-Emesis (FLIE) questionnaire after the first cycle of platinum-based chemotherapy.
|
During the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Signs and Symptoms, Digestive
- Respiratory Tract Diseases
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Lung Neoplasms
- Vomiting
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Azoles
- Imidazoles
- Indoles
- Heterocyclic Compounds, 3-Ring
- Carbazoles
- Ondansetron
Other Study ID Numbers
Other Study ID Numbers
- XWFT-2025-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.